HER2/ErbB2 (C-Term) Monoclonal Antibody

Human epidermal growth factor receptor 2 (HER2), also known as ErbB2 and Neu, is a cell surface receptor and member of the EGF family of receptor tyrosine kinases that is encoded by ERBB2 in humans.{56034} It is a transmembrane receptor composed of a C-terminal intracellular tyrosine kinase domain, a transmembrane lipophilic segment, and an N-terminal extracellular domain, that is expressed at low levels in various epithelial tissues, as well as breast, lung, kidney, ovary, placenta, and the gastrointestinal tract.{56035} Unlike other EGF receptors, HER2 does not bind ligands or undergo a conformational change in its extracellular domain for activation. HER2 is activated upon heterodimerization with HER3 or HER4, which stabilizes ligand binding to HER3 and HER4, or homodimerization and enhances kinase-mediated activation of the MAPK and PI3K cellular signaling pathways.{56034,56035} Truncated forms of HER2 with constitutive oncogenic activity can be generated by proteolytic cleavage of the extracellular domain.{56035} ERBB2 is overexpressed in 12 to 15% of breast cancer tumors and is associated with accelerated growth rate, increased rate of recurrence, and poor overall survival.{56035} Various mutations in ERBB2, with or without gene amplification, have been found in prostate, colon, bladder, breast, lung, and colorectal tumors, as well as metastatic cutaneous squamous small cell carcinomas.{56037,56036} Cayman's HER2/ErbB2 (C-Term) Monoclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications.